✦ LIBER ✦

Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis

✍ Scribed by Iwakiri, Katsuhiko; Umegaki, Eiji; Hiramatsu, Naoki; Sakurai, Yuuichi; Hori, Tetsuharu; Kudou, Kentarou; Nishimura, Akira; Ashida, Kiyoshi

Book ID: 122243019
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 51 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)62682-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tu1052 A Phase 3, Randomized, Double-Bli

Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis

✍ Umegaki, Eiji; Iwakiri, Katsuhiko; Hiramatsu, Naoki; Sakurai, Yuuichi; Hori, Tet 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 390 KB

Mo1053 A Phase 2, Randomized, Double-Bli

Mo1053 A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis

✍ Chiba, Tsutomu; Sakurai, Yuuichi; Nishimura, Akira; Hiramatsu, Naoki; Umegaki, E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 325 KB

A Multicenter, Prospective, Randomized,

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

✍ Jani, Rajendrakumar H.; Pai, Vikas; Jha, Pramod; Jariwala, Gunjan; Mukhopadhyay, 📂 Article 📅 2014 🏛 Mary Ann Liebert 🌐 English ⚖ 365 KB